$ARMP
Armata Pharmaceuticals, Inc.

2014 Q1 Form 10-Q Financial Statement

#000114420414032483 Filed on May 20, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q1 2013
Revenue $104.0K $22.00K $81.00K
YoY Change 372.73% -87.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.630M $690.0K $6.000M
YoY Change 136.23% 88.68%
% of Gross Profit
Research & Development $1.011M $551.0K $6.469M
YoY Change 83.48% 337.09%
% of Gross Profit
Depreciation & Amortization $18.00K $24.00K $82.00K
YoY Change -25.0% 36.67%
% of Gross Profit
Operating Expenses $2.638M $1.235M $12.47M
YoY Change 113.6% 167.49%
Operating Profit -$2.534M -$1.213M -$12.38M
YoY Change 108.9%
Interest Expense $0.00 $96.00K $233.0K
YoY Change -100.0% -168.53%
% of Operating Profit
Other Income/Expense, Net $0.00 -$300.0K $52.20M
YoY Change -100.0% 40053.08%
Pretax Income -$11.31M -$1.620M -$64.58M
YoY Change 598.15% 1426.71%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.31M -$1.612M -$64.58M
YoY Change 601.43% 5879.91%
Net Earnings / Revenue -10872.12% -7327.27% -79732.1%
Basic Earnings Per Share -$0.64
Diluted Earnings Per Share -$377.0M -$162.0M -$0.64
COMMON SHARES
Basic Shares Outstanding 101.2M shares
Diluted Shares Outstanding 101.2M shares

Balance Sheet

Concept 2014 Q1 2013 Q1 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.44M $20.36M
YoY Change 2267.44%
Cash & Equivalents $16.44M $719.0K $20.36M
Short-Term Investments
Other Short-Term Assets $350.0K $300.0K
YoY Change -61.04%
Inventory
Prepaid Expenses
Receivables $12.00K $10.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $16.73M $20.66M
YoY Change 1152.12%
LONG-TERM ASSETS
Property, Plant & Equipment $356.0K $150.0K
YoY Change 7.14%
Goodwill $4.329M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $17.62M $20.55M
YoY Change 0.64%
TOTAL ASSETS
Total Short-Term Assets $16.73M $20.66M
Total Long-Term Assets $17.62M $20.55M
Total Assets $34.35M $41.21M
YoY Change 86.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $890.0K $2.150M
YoY Change 10.82%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $879.0K $2.390M
YoY Change -60.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $66.44M $57.66M
YoY Change
Total Long-Term Liabilities $57.58M $57.66M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $879.0K $2.390M
Total Long-Term Liabilities $57.58M $57.66M
Total Liabilities $58.46M $63.13M
YoY Change 591.46%
SHAREHOLDERS EQUITY
Retained Earnings -$394.8M
YoY Change
Common Stock $1.825M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$24.11M -$21.92M
YoY Change
Total Liabilities & Shareholders Equity $34.35M $41.21M
YoY Change 86.72%

Cashflow Statement

Concept 2014 Q1 2013 Q1 2013
OPERATING ACTIVITIES
Net Income -$11.31M -$1.612M -$64.58M
YoY Change 601.43% 5879.91%
Depreciation, Depletion And Amortization $18.00K $24.00K $82.00K
YoY Change -25.0% 36.67%
Cash From Operating Activities -$3.690M -$1.120M -$6.290M
YoY Change 229.46% 46.96%
INVESTING ACTIVITIES
Capital Expenditures $229.0K $0.00 $102.0K
YoY Change -304.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$230.0K $0.00 -$100.0K
YoY Change -103.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $0.00 $16.89M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 980.0K 25.89M
YoY Change -100.0% 2625.26%
NET CHANGE
Cash From Operating Activities -3.690M -1.120M -6.290M
Cash From Investing Activities -230.0K 0.000 -100.0K
Cash From Financing Activities 0.000 980.0K 25.89M
Net Change In Cash -3.920M -140.0K 19.50M
YoY Change 2700.0% -8578.26%
FREE CASH FLOW
Cash From Operating Activities -$3.690M -$1.120M -$6.290M
Capital Expenditures $229.0K $0.00 $102.0K
Free Cash Flow -$3.919M -$1.120M -$6.392M
YoY Change 249.91% 51.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Trading Symbol
TradingSymbol
APHB
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
182535562 shares
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
AmpliPhi Biosciences Corp
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000921114
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10148000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
13005000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8000 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
280000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
171000 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
16727000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16435000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20355000 USD
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
20534000 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
356000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145000 USD
CY2014Q1 aphb In Process Research And Development
InProcessResearchAndDevelopment
12939000 USD
CY2013Q4 aphb In Process Research And Development
InProcessResearchAndDevelopment
12939000 USD
CY2014Q1 us-gaap Goodwill
Goodwill
4329000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
4329000 USD
CY2014Q1 us-gaap Assets
Assets
34351000 USD
CY2013Q4 us-gaap Assets
Assets
37947000 USD
CY2014Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
879000 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2147000 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
879000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2147000 USD
CY2014Q1 aphb Derivative Preferred Shares Conversion Liability
DerivativePreferredSharesConversionLiability
38807000 USD
CY2013Q4 aphb Derivative Preferred Shares Conversion Liability
DerivativePreferredSharesConversionLiability
33510000 USD
CY2014Q1 aphb Derivative Warrants Liability
DerivativeWarrantsLiability
18772000 USD
CY2013Q4 aphb Derivative Warrants Liability
DerivativeWarrantsLiability
16511000 USD
CY2014Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
57579000 USD
CY2013Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
50021000 USD
CY2014Q1 us-gaap Liabilities
Liabilities
58458000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
52168000 USD
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
89000 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
89000 USD
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
1825000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1825000 USD
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
367044000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
366782000 USD
CY2014Q1 us-gaap Other Additional Capital
OtherAdditionalCapital
1837000 USD
CY2013Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
1837000 USD
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-69000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-65000 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394833000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-384689000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-24107000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-14221000 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34351000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37947000 USD
CY2014Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
491000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
473000 USD
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
8859978 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
8859978 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
8859978 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
8859978 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
445000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
445000000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
182535562 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
182535562 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
182535562 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
182535562 shares
CY2013Q1 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
22000 USD
CY2013 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
325000 USD
CY2014Q1 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
0 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
551000 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6502000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1006000 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
684000 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6259000 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1580000 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
1235000 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
12761000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2586000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1213000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-12436000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2586000 USD
CY2013Q1 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
0 USD
CY2013 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
40562000 USD
CY2014Q1 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
7558000 USD
CY2013Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
303000 USD
CY2013 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2630000 USD
CY2014Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2013Q1 us-gaap Interest Expense
InterestExpense
96000 USD
CY2013 us-gaap Interest Expense
InterestExpense
233000 USD
CY2014Q1 us-gaap Interest Expense
InterestExpense
0 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-1612000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-55861000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-10144000 USD
CY2013Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2013 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
8464000 USD
CY2014Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
8464000 USD
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1612000 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-64325000 USD
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18608000 USD
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66908810 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
101201753 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
182535562 shares
CY2013Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-113000 USD
CY2013 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
41000 USD
CY2014Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4000 USD
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1725000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55820000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1437000 USD
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
262000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
2635000 USD
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3000000 USD
CY2013 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 USD
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
50000 USD
CY2013 aphb Stock Issued During Period Value New Issues1
StockIssuedDuringPeriodValueNewIssues1
50000 USD
CY2013 aphb Deemed Dividend On Preferred Stock
DeemedDividendOnPreferredStock
0 USD
CY2013 aphb Stock Issued During Period Value Conversion Of Convertible Securities1
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
5957000 USD
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000 USD
CY2013 aphb Stock Issued During Period Value Shares Released From Escrow
StockIssuedDuringPeriodValueSharesReleasedFromEscrow
0 USD
CY2013 aphb Stock Issued During Period Value New Issues2
StockIssuedDuringPeriodValueNewIssues2
15452000 USD
CY2013 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
41000 USD
CY2014Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-4000 USD
CY2013Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
3000000 USD
CY2014Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2013Q1 aphb Fairvalue Of Warrants Issued As Investment Fees
FairvalueOfWarrantsIssuedAsInvestmentFees
0 USD
CY2013 aphb Fairvalue Of Warrants Issued As Investment Fees
FairvalueOfWarrantsIssuedAsInvestmentFees
759000 USD
CY2014Q1 aphb Fairvalue Of Warrants Issued As Investment Fees
FairvalueOfWarrantsIssuedAsInvestmentFees
0 USD
CY2013Q1 us-gaap Depreciation
Depreciation
24000 USD
CY2013 us-gaap Depreciation
Depreciation
82000 USD
CY2014Q1 us-gaap Depreciation
Depreciation
18000 USD
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
154000 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1437000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
262000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-12000 USD
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4000 USD
CY2013Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-618000 USD
CY2013 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-618000 USD
CY2014Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
0 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-379000 USD
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
210000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1268000 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
222000 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
23000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
109000 USD
CY2013Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
96000 USD
CY2013 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
233000 USD
CY2014Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1006000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6338000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3687000 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
102000 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
229000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-102000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-229000 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16892000 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
CY2013 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
7000000 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
CY2013Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
976000 USD
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2000000 USD
CY2014Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
976000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
25892000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2013Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-113000 USD
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
41000 USD
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-4000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-143000 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
19493000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3920000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
862000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
719000 USD
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Use of Estimates</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2014Q1 aphb Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriod
0 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
25721000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10089662 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.19
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2014Q1 us-gaap Share Price
SharePrice
0.58
CY2013Q4 us-gaap Share Price
SharePrice
0.50
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2261000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.19
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.20
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24859834 shares
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
54494503 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
152456912 shares
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
154000 USD
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1437000 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
262000 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
25721000 shares
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M17D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y10M20D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8416233 USD
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4049376 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
40000000 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
38425745 shares
CY2014Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
104146745 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0.58
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2072890 USD
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2014Q1 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
three to seven years

Files In Submission

Name View Source Status
0001144204-14-032483-index-headers.html Edgar Link pending
0001144204-14-032483-index.html Edgar Link pending
0001144204-14-032483.txt Edgar Link pending
0001144204-14-032483-xbrl.zip Edgar Link pending
aphb-20140331.xml Edgar Link completed
aphb-20140331.xsd Edgar Link pending
aphb-20140331_cal.xml Edgar Link unprocessable
aphb-20140331_def.xml Edgar Link unprocessable
aphb-20140331_lab.xml Edgar Link unprocessable
aphb-20140331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v377687_10q.htm Edgar Link pending
v377687_ex31-1.htm Edgar Link pending
v377687_ex31-2.htm Edgar Link pending
v377687_ex32-1.htm Edgar Link pending
v377687_ex32-2.htm Edgar Link pending